Prediction of Coreceptor Tropism in HIV-1 Subtype C in Botswana.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
31 01 2023
Historique:
received: 31 12 2022
revised: 25 01 2023
accepted: 26 01 2023
entrez: 28 2 2023
pubmed: 1 3 2023
medline: 3 3 2023
Statut: epublish

Résumé

It remains unknown whether the C-C motif chemokine receptor type 5 (CCR5) coreceptor is still the predominant coreceptor used by Human Immunodeficiency Virus-1 (HIV-1) in Botswana, where the HIV-1 subtype C predominates. We sought to determine HIV-1C tropism in Botswana using genotypic tools, taking into account the effect of antiretroviral treatment (ART) and virologic suppression. HIV-1 gp120 V3 loop sequences from 5602 participants were analyzed for viral tropism using three coreceptor use predicting algorithms/tools: Geno2pheno, HIV-1C Web Position-Specific Score Matrices (WebPSSM) and the 11/25 charge rule. We then compared the demographic and clinical characteristics of people living with HIV (PLWH) harboring R5- versus X4-tropic viruses using χ

Identifiants

pubmed: 36851617
pii: v15020403
doi: 10.3390/v15020403
pmc: PMC9963705
pii:
doi:

Substances chimiques

Anti-Retroviral Agents 0

Banques de données

ClinicalTrials.gov
['NCT01965470']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : FIC NIH HHS
ID : K43 TW012350
Pays : United States
Organisme : NHGRI NIH HHS
ID : U41 HG006941
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009610
Pays : United States
Organisme : PEPFAR
ID : U01 GH000447
Pays : United States
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom

Références

N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):397-404
pubmed: 24189148
J Clin Microbiol. 2011 Sep;49(9):3380-2
pubmed: 21734029
Virology. 2006 Apr 10;347(2):247-60
pubmed: 16406460
AIDS. 2019 May 1;33(6):1073-1082
pubmed: 30946161
Nat Biotechnol. 2007 Dec;25(12):1407-10
pubmed: 18066037
AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):343-52
pubmed: 11897036
Nature. 1996 Jun 20;381(6584):661-6
pubmed: 8649511
J Virol. 2003 Dec;77(24):13376-88
pubmed: 14645592
Nature. 1996 Jun 20;381(6584):667-73
pubmed: 8649512
AIDS Res Hum Retroviruses. 2012 Apr;28(4):324-32
pubmed: 21819257
AIDS Res Hum Retroviruses. 2014 May;30(5):436-45
pubmed: 24205895
AIDS Res Hum Retroviruses. 2017 May 25;33(11):1083-1098
pubmed: 28540766
Virology. 1998 Feb 15;241(2):181-8
pubmed: 9499793
Lancet Infect Dis. 2011 May;11(5):394-407
pubmed: 21429803
J Virol. 1999 Aug;73(8):6271-81
pubmed: 10400718
J Infect Dis. 2006 Oct 1;194(7):926-30
pubmed: 16960780
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):9-15
pubmed: 20921899
PLoS One. 2017 Aug 25;12(8):e0182384
pubmed: 28841646
Sci Rep. 2019 Jul 10;9(1):9997
pubmed: 31292462
PLoS One. 2013 Jul 09;8(7):e68076
pubmed: 23874501
J Microbiol. 2012 Oct;50(5):869-73
pubmed: 23124759
AIDS Patient Care STDS. 2007 Sep;21(9):702
pubmed: 17919097
AIDS Res Ther. 2020 Feb 7;17(1):5
pubmed: 32033571
Nucleic Acids Res. 2014 Oct;42(18):e144
pubmed: 25120265
Lancet HIV. 2020 Jun;7(6):e422-e433
pubmed: 32504575
J Infect Dis. 2007 Jul 15;196(2):328-9; author reply 329-30
pubmed: 17570122
J Exp Med. 1997 Feb 17;185(4):621-8
pubmed: 9034141
J Antimicrob Chemother. 2015 May;70(5):1391-5
pubmed: 25608585
Sci Rep. 2016 Apr 29;6:24883
pubmed: 27126912
Lancet Infect Dis. 2015 Mar;15(3):259-61
pubmed: 25749217
J Clin Microbiol. 2015 Aug;53(8):2581-92
pubmed: 26041893
J Antimicrob Chemother. 2011 Apr;66(4):890-5
pubmed: 21393136
J Virol. 2003 Jul;77(13):7682-8
pubmed: 12805470
J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):233-40
pubmed: 21709569
BMC Bioinformatics. 2010 Oct 05;11:494
pubmed: 20923564
Infect Genet Evol. 2013 Oct;19:337-48
pubmed: 23660484
J Acquir Immune Defic Syndr. 2011 May 1;57(1):46-50
pubmed: 21346588

Auteurs

Kenanao Kotokwe (K)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Sikhulile Moyo (S)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Melissa Zahralban-Steele (M)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Molly Pretorius Holme (MP)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Pinkie Melamu (P)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Catherine Kegakilwe Koofhethile (CK)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Wonderful Tatenda Choga (WT)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Terence Mohammed (T)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Tapiwa Nkhisang (T)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Baitshepi Mokaleng (B)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Dorcas Maruapula (D)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Tsotlhe Ditlhako (T)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Ontlametse Bareng (O)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Patrick Mokgethi (P)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Corretah Boleo (C)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.

Joseph Makhema (J)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Shahin Lockman (S)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Max Essex (M)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Manon Ragonnet-Cronin (M)

Department of Ecology and Evolution, The University of Chicago, Chicago, IL 60637, USA.

Vlad Novitsky (V)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Simani Gaseitsiwe (S)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Gaborone, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH